Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
25 Results for "
PROTAC HPK1 Degrader
" in MedChemExpress (MCE) Product Catalog:
Products (25)
25 Results for "PROTAC HPK1 Degrader" in MCE Product Catalog:
Cat. No.: HY-163372
CAS No.: 3034182-97-0
PROTAC HPK1 Degrader-1 (compound B1) is a PROTAC degrader that recruits cereblon to induce HPK1 degradation, with a DC50 of 1.8 nM. PROTAC HPK1 Degrader-1 inhibits HPK1 kinase activity, with an IC50 of 140.5 nM. PROTAC HPK1 Degrader-1 suppresses the phosphorylation of SLP76 protein, with an IC50 of 496.1 nM. PROTAC HPK1 Degrader-1 can be used to investigate non-kinase-dependent signaling of HPK1 in the TCR pathway and cancer-related research .
Cat. No.: HY-162544
CAS No.: 2893885-31-7
PROTAC HPK1 Degrader-2 (compound 3) is a PROTAC degrader targeting hematopoietic progenitor kinase MAP4K1/HPK1, with a DC50 of 23 nM in human PBMCs. PROTAC HPK1 Degrader-2 is applicable for cancer research .
Cat. No.: HY-174135
Target:
Research Areas:
PROTAC HPK1 Degrader-4 is an orally active HPK1 PROTAC degrader and immune activator, with DC50 values of 3.16 nM and 72.59 nM in Jurkat cells and PBMCs, respectively. PROTAC HPK1 Degrader-4 induces degradation via the ubiquitin-proteasome system, downregulates the HPK1-SLP76 signaling pathway, reduces the phosphorylation level of SLP76 (S376), and promotes immune activation. PROTAC HPK1 Degrader-4 can be used in the research of colorectal cancer and B-cell lymphoma .
Cat. No.: HY-175547
CAS No.: 3108744-13-1
PROTAC HPK1 Degrader-5 is an orally effective and selective HPK1 PROTAC degrader with a DC50 of 5.0 nM. PROTAC HPK1 Degrader-5 recruits the CRBN E3 ligase to specifically induce the degradation of HPK1 via the ubiquitin-proteasome system, which in turn significantly inhibits SLP76 phosphorylation and enhances the activation of the ERK pathway, thereby stimulating the release of IL-2 and IFN-γ. PROTAC HPK1 Degrader-5 can be used in studies related to tumor immunity (e.g., colorectal cancer) .
Cat. No.: HY-162816
PROTAC HPK1 Degrader-3 is an orally active, PROTAC degrader that selectively targets HPK1, with a DC50 of 21.26 nM. PROTAC HPK1 Degrader-3 induces HPK1 degradation via the ubiquitin-proteasome system and forms a stable ternary complex with HPK1 and CRBN. It inhibits the SLP76 and NF-κB signaling pathways, enhances MAPK signal transduction, reverses the immunosuppressive factor-mediated inhibition of T cell cytokine secretion, and promotes the secretion of T cell immune cytokines. PROTAC HPK1 Degrader-3 suppresses tumor growth and enhances anti-PD-L1-mediated antitumor activity. It can be used in studies related to malignant tumors, such as colorectal cancer .
Cat. No.: HY-175551
CAS No.: 3061690-80-7
Research Areas:
HPK1 ligand-Linker Conjugate 1 is a synthesized target protein ligand-linker conjugate that can be used for synthesis of PROTACs, such as PROTAC HPK1 Degrader-5 (HY-175547). PROTAC HPK1 Degrader-5 is a potent and orally active HPK1 PROTAC degrader with anti-tumor activity .
Cat. No.: HY-184230
CAS No.: 3120899-50-2
Target:
Research Areas:
PROTAC HPK1 Degrader-8 is a HPK1 PROTAC degrader with a DC50 of 1-10 nM. PROTAC HPK1 Degrader-8 promotes HPK1 ubiquitination and degradation. PROTAC HPK1 Degrader-8 induces IL-2 production, with an EC50 of 3 nM. PROTAC HPK1 Degrader-8 can be used in research related to hematologic malignancies and solid tumors .
Cat. No.: HY-179727
Target:
Research Areas:
PROTAC HPK1 Degrader-7 (compound D02) is a potent and selective PROTAC HPK1 degrader with an DC50 of 3.07 nM. PROTAC HPK1 Degrader-7 exhibits selectivity over GLK. PROTAC HPK1 Degrader-7 induces HPK1 degradation in a CRBN- and proteasome-dependent manner. PROTAC HPK1 Degrader-7 inhibits SLP-76 phosphorylation, induces IL-2 and IFN-γ secretion in human primary T cells. PROTAC HPK1 Degrader-7 can be used for immunology research .
Cat. No.: HY-146231
CAS No.: 2636072-62-1
Research Areas:
SS47 is a hematopoietic progenitor kinase HPK1 PROTAC-class degrader and immune activator. SS47 promotes the proliferation of CD4+ and CD8+ T cells as well as IFN-γ secretion, and enhances the anti-tumor cytotoxicity and in vivo efficacy of BCMA CAR-T cells. SS47 also inhibits tumor growth in mouse models, and when combined with anti-PD-1 therapy, it improves the immune response of 4T1 tumor-bearing mice. SS47 can be used in breast cancer-related research .
Cat. No.: HY-146231A
Purity: 99.88%
SS47 TFA is a hematopoietic progenitor kinase HPK1 PROTAC-class degrader and immune activator. SS47 TFA promotes the proliferation of CD4+ and CD8+ T cells as well as IFN-γ secretion, and enhances the anti-tumor cytotoxicity and in vivo efficacy of BCMA CAR-T cells. SS47 TFA also inhibits tumor growth in mouse models, and when combined with anti-PD-1 therapy, it improves the immune response of 4T1 tumor-bearing mice. SS47 TFA can be used in breast cancer-related research .
Cat. No.: HY-174357
Research Areas:
HPK1 ligand 3-dimethylph tetrahydropyridine is a Target Protein Ligand-Linker Conjugate. HPK1 ligand 3-dimethylph tetrahydropyridine can be used to synthesize PROTAC HPK1 Degrader-4 (HY-174135) .
Cat. No.: HY-W761300
CAS No.: 2446913-96-6
Target:
Research Areas:
1-(4-Pip-Ph)-DHP-dione is an E3 ligase ligand. 1-(4-Pip-Ph)-DHP-dione can be used for synthesis of PROTAC HPK1 Degrader-2 (HY-162544) .
Cat. No.: HY-162545
CAS No.: 2893885-42-0
Research Areas:
HPK1-IN-47 is a HPK1 ligand. HPK1-IN-47 can be used for synthesis of PROTACs, such as PROTAC HPK1 Degrader-2 (HY-162544). HPK1-IN-47 can be used for research of HPK1-mediated diseases including cancer .
Cat. No.: HY-174355
Research Areas:
HPK1 ligand 3 is a ligand for target protein for PROTAC that can be used to synthesize PROTAC HPK1 Degrader-4 (HY-174135) .
Cat. No.: HY-162841
Research Areas:
HPK1 ligand 1 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). HPK1 ligand 1 can be used for synthesis PROTAC PD-L1 degrader-2 (HY-162816) .
Cat. No.: HY-162546
Research Areas:
3-hydroxypropanoic acid-pip-hydroquinone-dihydrouracil is a conjugate of E3 ligase ligand and linker that serve as a key intermediate for the synthesis of complete PROTAC HPK1 Degrader-2 (HY-162544) .
Cat. No.: HY-168282
CAS No.: 3047066-15-6
Target:
Research Areas:
DD205-291 is a selective, orally active HPK1 PROTAC degrader with a DC50 of 8.8 nM. By inducing complete degradation of HPK1 protein, DD205-291 simultaneously blocks both its kinase-dependent functions and non-kinase scaffold functions. DD205-291 inhibits the phosphorylation of SLP-76 with an EC50 of 22.98 nM. DD205-291 induces the production of IL-2 and IFN-γ with EC50 values of 34.68 nM and 32.6 nM, respectively. Combined with anti-PD1 in mouse models, DD205-291 exerts tumor-suppressive effects with favorable safety profiles. DD205-291 can be used in colon cancer-related research .
Cat. No.: HY-179731
Research Areas:
HPK1-IN-67, a HPK1 inhibitor, is a ligand for target protein for PROTAC. HPK1-IN-67 can be used for synthesis of PROTACs, such as PROTAC HPK1 Degrader-7 (HY-179727) .
Cat. No.: HY-175549
Research Areas:
HPK1 ligand 4 is a PROTAC target protein ligand that can be used for synthesis of PROTACs, such as PROTAC HPK1 Degrader-5 (HY-175547). PROTAC HPK1 Degrader-5 is a potent and orally active HPK1 PROTAC degrader with anti-tumor activity .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
